BR112021000201A2 - composição farmacêutica contendo um peptídeo - Google Patents

composição farmacêutica contendo um peptídeo Download PDF

Info

Publication number
BR112021000201A2
BR112021000201A2 BR112021000201-4A BR112021000201A BR112021000201A2 BR 112021000201 A2 BR112021000201 A2 BR 112021000201A2 BR 112021000201 A BR112021000201 A BR 112021000201A BR 112021000201 A2 BR112021000201 A2 BR 112021000201A2
Authority
BR
Brazil
Prior art keywords
cys
tyr
vehicle
asn
glu
Prior art date
Application number
BR112021000201-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher RUPP
Ronny Schulze
Rob Van Den Akker
Kuldeep Bhokare
Jörn Lüders
George Shlieout
Jörg Hagedorn
Original Assignee
Abbott Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories Gmbh filed Critical Abbott Laboratories Gmbh
Publication of BR112021000201A2 publication Critical patent/BR112021000201A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112021000201-4A 2018-07-09 2019-07-08 composição farmacêutica contendo um peptídeo BR112021000201A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201811025533 2018-07-09
IN201811025533 2018-07-09
PCT/IB2019/000716 WO2020012243A2 (en) 2018-07-09 2019-07-08 Pharmaceutical composition containing a peptide

Publications (1)

Publication Number Publication Date
BR112021000201A2 true BR112021000201A2 (pt) 2021-08-10

Family

ID=68165587

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000201-4A BR112021000201A2 (pt) 2018-07-09 2019-07-08 composição farmacêutica contendo um peptídeo

Country Status (6)

Country Link
AR (1) AR115724A1 (es)
BR (1) BR112021000201A2 (es)
CL (1) CL2021000022A1 (es)
CO (1) CO2021000158A2 (es)
MX (1) MX2021000312A (es)
WO (1) WO2020012243A2 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033427A1 (en) 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
MX2020005326A (es) 2008-08-15 2022-03-03 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
EP2238979A1 (en) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP2016521249A (ja) 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
WO2016024291A1 (en) 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
EP3233059A1 (en) * 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide

Also Published As

Publication number Publication date
AR115724A1 (es) 2021-02-17
CL2021000022A1 (es) 2021-07-19
WO2020012243A3 (en) 2020-03-05
MX2021000312A (es) 2021-06-08
CO2021000158A2 (es) 2021-01-18
WO2020012243A2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
US20210290554A1 (en) Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
PT2079445E (pt) Composições de enzimas digestivas estáveis
JP2009531275A5 (es)
US20150132375A1 (en) Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
BRPI0707616A2 (pt) formulaÇÕes para um efetor de junÇço oclusiva
BR112012021275B1 (pt) Formulação compreendendo um adsorvente misturado com carragenina, para entrega oral e liberação controlada de adsorventes no intestino, e, uso de uma formulação
US20100068290A1 (en) Coated pellets
US20230113303A1 (en) Granular Pharmaceutical Composition
CN107693515B (zh) 含碱化剂和艾曲泊帕的药物组合物及其用途
BR112021000201A2 (pt) composição farmacêutica contendo um peptídeo
JP2004051502A (ja) 成長ホルモン含有安定化粉末製剤
KR100289141B1 (ko) 펩타이드의 경구 투여를 위한 안정화된 조성물
TWI531374B (zh) 適於口服之gc-c受體激動劑多肽之穩定固態調配物
JPH02207A (ja) 塩酸ブロムヘキシン含有製剤
TW201440782A (zh) 米卡芬淨或其鹽的醫藥組成物
EA040381B1 (ru) Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения